DxBio presents an innovative platform combining CRISPR-based diagnostics, Artificial Intelligence (AI), and microfluidics for early pathogen detection. This approach promises fast, accurate, and cost-effective solutions for global health threats such as Antimicrobial Resistance (AMR) detection, transforming global healthcare. Our approach aims to provide scalable, affordable and effective solutions that address critical gaps in AMR detection to better predict the resistance pattern against existing antibiotics.
.svg)
.png)
At DxBio, we are dedicated to advancing the field of Antimicrobial Resistance (AMR) through the development of innovative diagnostic solutions. By integrating CRISPR gene editing, Artificial Intelligence (AI), and Microfluidics, we offer cutting-edge technologies that enable rapid, accurate, and cost-effective detection of AMR. Our mission is to empower healthcare providers, researchers, and public health organizations with the tools needed to detect, understand, and combat AMR globally.
.png)
.png)
.png)
.png)
Our diagnostics provide accurate, trusted results that healthcare providers and patients rely on for informed decision-making.
Seamlessly integrated into healthcare workflows, our solutions ensure quick diagnostics, enabling timely clinical responses without compromising on quality.
Our platform makes AMR detection accessible and affordable, broadening its reach across healthcare systems.
Designed to perform reliably under varied conditions, our technology ensures accurate results in a wide range of assay environments, making it ideal for both point-of-care and field settings.
Our flexible technology is capable of targeting multiple molecular markers, supporting multiplexing formats, and integrating with legacy systems to address a broad spectrum of diagnostic needs.
.svg)
do the honors,
hover over the button!
do the honors,
hover over the button!
.png)
.png)
Powered by
